NUVB Company Profile and Key Details
Nuvation Bio
Price Chart
Stock Price Today
Nuvation Bio Inc. (NUVB) stock declined over -2.28%, trading at $4.73 on NYSE, down from the previous close of $4.84. The stock opened at $4.77, fluctuating between $4.70 and $4.87 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 12, 2026 | 4.75 | 4.88 | 4.66 | 4.84 | 2.54M |
| May 11, 2026 | 4.71 | 4.86 | 4.71 | 4.76 | 2.78M |
| May 08, 2026 | 4.82 | 4.91 | 4.70 | 4.79 | 2.91M |
| May 07, 2026 | 5.05 | 5.14 | 4.72 | 4.81 | 4.42M |
| May 06, 2026 | 4.95 | 5.17 | 4.81 | 5.04 | 6.33M |
| May 05, 2026 | 4.37 | 4.85 | 4.12 | 4.83 | 10.88M |
| May 04, 2026 | 4.48 | 4.84 | 4.39 | 4.41 | 7.7M |
| Apr 30, 2026 | 4.41 | 4.49 | 4.33 | 4.45 | 4.8M |
| Apr 29, 2026 | 4.50 | 4.52 | 4.22 | 4.34 | 3.3M |
| Apr 28, 2026 | 4.59 | 4.62 | 4.46 | 4.56 | 4.56M |
| Apr 27, 2026 | 4.87 | 5.15 | 4.55 | 4.56 | 6.54M |
| Apr 23, 2026 | 5.13 | 5.23 | 4.98 | 5.04 | 2.15M |
| Apr 22, 2026 | 5.26 | 5.29 | 5.09 | 5.12 | 2.5M |
| Apr 21, 2026 | 5.14 | 5.25 | 5.03 | 5.11 | 3.58M |
| Apr 20, 2026 | 5.02 | 5.18 | 4.89 | 5.12 | 3.78M |
| Apr 17, 2026 | 4.90 | 5.10 | 4.85 | 5.08 | 2.7M |
| Apr 16, 2026 | 4.88 | 4.88 | 4.62 | 4.81 | 4.55M |
| Apr 14, 2026 | 4.75 | 4.91 | 4.72 | 4.85 | 2.33M |
| Apr 13, 2026 | 4.50 | 4.75 | 4.50 | 4.70 | 1.96M |
| Apr 10, 2026 | 4.65 | 4.65 | 4.38 | 4.60 | 3.3M |
Contact Details
About Company
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Company Information
| Employees | 273 |
| Beta | 1.51 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Chief Scientific Officer
Dr. David C. Hanley Ph.D.
Chief Technical Operations Officer
Dr. David Liu M.D., Ph.D.
Chief Medical Officer
Ms. Jennifer A. Fox
Chief Financial Officer & Sec.
Ms. Stacy Markel
Chief People Officer
Dr. David T. Hung M.D.
Founder, Pres, Chief Executive Officer & Director
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep